Tegafur + Uracil 100 mg/224 mg
Product Overview
| Generic Name | Tegafur + Uracil 100 mg/224 mg |
| Brand Name(s) | UFT, Uftoral, Tegura |
| Category | Antineoplastic / Cancer |
| Form | Capsule |
| Strength | 100mg / 224 mg per capsule |
| Therapeutic Class | Antineoplastic antimetabolite; oral fluoropyrimidine / 5-FU prodrug |
| ATC Code | L01BC53 |
Manufacturing & Regulatory
| Manufacturer | Cipla, Dr. Reddy's |
| GMP Compliance | WHO-GMP |
| COFEPRIS | 010.000.5446.01 |
| Free Sale Certificate | Yes, available as COPP/CPP |
Logistics & Export
| MOQ | 10 Units |
| Shelf Life | 24 Months |
| Storage | Store at 20–25 °C |
| Incoterms | Exw, HSN: 30049099 |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Supplied per batch upon request |
| SDS-Safety Data Sheet (PDF) | cytotoxic oncology product |
| CTD Summary (PDF) | CTD available to regulators; summary available to qualified partners |
Special Notes
Tegafur is an oral prodrug of 5-fluorouracil (5-FU) used in oncology, commonly in fixed combinations such as Tegafur/Uracil or Tegafur/Gimeracil/Oteracil. It is used mainly for colorectal and gastric cancers, with other uses varying by jurisdiction and treatment protocol